US OptionsDetailed Quotes

ACXP241115C4000

Watchlist
  • 0.00
  • 0.000.00%
15min DelayClose Nov 15 09:30 ET
0.00High0.00Low
Intraday
  • 5D
  • Daily

No Data

News

Comments

    Stock_Drift
    Stock_Drift
    Sep 26 06:15
    Picture
    1
    Jaguar8
    Jaguar8
    Sep 26 06:13
    NEWS
    $Acurx Pharmaceuticals (ACXP.US)$
    Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues
    Acurx Pharmaceuticals (NASDAQ: ACXP)announced new analyses extending data on ibezapolstat's beneficial effects on the gut microbiome for C. difficile Infection (CDI) treatment. The data showed increased beneficial bacteria, reversing dysbiosis and contributing to CDI anti-recurrence. Ibezapolstat's favorable pharmacokinetics were c...
    Trytosaveabit
    Trytosaveabit
    Sep 26 06:05
    Update
    $Acurx Pharmaceuticals (ACXP.US)$ Reuters· 3 mins ago
    Acurx Announces Additional Ibezapolstat Ph2B Results in Cdi as Well as Anthrax (B. Anthracis) Susceptibility to Acx-375 Analogues
    Jaguar8
    Jaguar8
    Sep 24 06:49
    NEWS
    $Acurx Pharmaceuticals (ACXP.US)$
    Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium
    Acurx Pharmaceuticals (NASDAQ: ACXP) announced results from its research on ibezapolstat in collaboration with Leiden University Medical Center (LUMC) at the International C. difficile Symposium. The research revealed high-resolution details of ibezapolstat's interaction with its mole...
    Trytosaveabit
    Trytosaveabit
    Aug 12 05:48
    Possible upcoming catalysts
    $Acurx Pharmaceuticals (ACXP.US)$ Along with the FDA answer coming on phase 3!  (((((.  ·Throughout the rest of this year, they will continue to roll out our Phase 2 results in either oral presentations or scientific posters (in some cases both), which will include results from new analyses as data become available, at various prominent scientific conferences including:
    oIn September 2024, the World Antimicrobial Resistance conference in Philadelphia;oIn September 2024,...
Read more